AR073796A1 - Formulaciones de corticosteroides y sus metodos de tratamiento - Google Patents

Formulaciones de corticosteroides y sus metodos de tratamiento

Info

Publication number
AR073796A1
AR073796A1 ARP090103875A ARP090103875A AR073796A1 AR 073796 A1 AR073796 A1 AR 073796A1 AR P090103875 A ARP090103875 A AR P090103875A AR P090103875 A ARP090103875 A AR P090103875A AR 073796 A1 AR073796 A1 AR 073796A1
Authority
AR
Argentina
Prior art keywords
formulation
mometasone furoate
lower airways
diseases
formulations
Prior art date
Application number
ARP090103875A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR073796A1 publication Critical patent/AR073796A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Esta presentacion se relaciona con soluciones esteroidales para la preparacion de medicamentos y fármacos utiles para tratar enfermedades de las vías aéreas superiores e inferiores. Varias versiones del presente invento ofrecen formulaciones, formas de formulaciones y dosis con furoato de mometasona en estado disuelto adecuado para inhalacion que puede utilizarse para el tratamiento de enfermedades de las vías aéreas superiores y/o inferiores. Reivindicacion 7: La formulacion de la reivindicacion 1, en la que la formulacion comprende al menos un co-solvente. Reivindicacion 12: La formulacion de la reivindicacion 1, en la que la formulacion comprende al menos un surfactante. Reivindicacion 13: La formulacion de la reivindicacion 1, en la que la formulacion comprende al menos un surfactante y al menos un aceite. Reivindicacion 24: La formulacion de la reivindicacion 1 comprende además al menos un agente modificatorio de reología. Reivindicacion 29: La formulacion de la reivindicacion 1 comprende además un descongestivo. Reivindicacion 46: Un método para tratar enfermedades en la vía aérea que comprende la administracion de una solucion de furoato de mometasona adecuada para inhalacion una vez al día en las vías aéreas superiores o inferiores cuando la dosis total diaria de furoato de mometasona va desde alrededor de 0,04 a alrededor de 200 microgramos.
ARP090103875A 2008-10-10 2009-10-08 Formulaciones de corticosteroides y sus metodos de tratamiento AR073796A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10451208P 2008-10-10 2008-10-10

Publications (1)

Publication Number Publication Date
AR073796A1 true AR073796A1 (es) 2010-12-01

Family

ID=41346680

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103875A AR073796A1 (es) 2008-10-10 2009-10-08 Formulaciones de corticosteroides y sus metodos de tratamiento

Country Status (8)

Country Link
US (1) US20120022032A1 (es)
EP (1) EP2349206A2 (es)
JP (1) JP2012505236A (es)
AR (1) AR073796A1 (es)
AU (1) AU2009302362A1 (es)
CA (1) CA2739353A1 (es)
TW (1) TW201026339A (es)
WO (1) WO2010042701A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB2465746B (en) * 2008-11-21 2011-02-16 Fortune Apex Dev Ltd Pharmaceutical composition for topical application
KR101749514B1 (ko) 2010-06-11 2017-06-21 레오 파마 에이/에스 비타민 ｄ 유사체 및 코르티코스테로이드를 포함하는 약제학적 분무 조성물
WO2015009776A1 (en) * 2013-07-19 2015-01-22 Merck Sharp & Dohme Corp. Low dose corticosteroid microemulsion compositions and methods of treatments thereof
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
HUE056448T2 (hu) * 2013-09-13 2022-02-28 Glenmark Specialty Sa Stabil, rögzített adagolású gyógyszerkészítmény, amely mometazont és olopatadint tartalmaz orrba történõ beadásra
US20170007704A1 (en) * 2015-07-09 2017-01-12 David Ram Carrier and pharmaceutical compositions for intrasinal delivery and uses thereof
CN114246331B (zh) * 2021-12-10 2023-03-24 江南大学 一种适用于慢性阻塞性肺疾病病人特殊医学用途的全营养配方食品

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
US6187765B1 (en) * 1997-10-09 2001-02-13 Schering Corporation Mometasone furoate suspensions for nebulization
DE69901936T2 (de) * 1998-01-30 2002-11-28 Novartis Consumer Health Sa Nasale lösungen
US20030178022A1 (en) * 2001-12-21 2003-09-25 Chiesi Farmaceutici S.P.A. Pressurized metered dose inhaler (PMDI) actuators and medicinal aerosol solution formulation products comprising therse actuators
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
US20060045850A1 (en) * 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
EP2486942B1 (en) * 2004-11-24 2018-10-10 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US8337814B2 (en) * 2005-12-15 2012-12-25 Topical Sinus Therapeutics, Inc. Treatment of active infections, sinusitis, rhinitis, and related neurological disorders and related compositions
WO2007075800A2 (en) * 2005-12-20 2007-07-05 Tika Läkemedel Ab Methods and systems for the delivery of corticosteroids
TW201414506A (zh) * 2006-04-21 2014-04-16 Toko Yakuhin Kogyo Kk 噴灑用凝膠型皮膚及／或黏膜附著型製劑及使用該製劑之投藥系統
MX2011000590A (es) * 2008-07-15 2011-03-01 Schering Corp Composiciones intranasales que comprenden un descongestionante y un corticosteroide.

Also Published As

Publication number Publication date
EP2349206A2 (en) 2011-08-03
US20120022032A1 (en) 2012-01-26
TW201026339A (en) 2010-07-16
WO2010042701A3 (en) 2011-02-17
AU2009302362A1 (en) 2010-04-15
WO2010042701A2 (en) 2010-04-15
CA2739353A1 (en) 2010-04-15
JP2012505236A (ja) 2012-03-01

Similar Documents

Publication Publication Date Title
AR073796A1 (es) Formulaciones de corticosteroides y sus metodos de tratamiento
JP2015157860A (ja) ヒトの皮膚の処置用の本質的に医薬有効成分を含まない発泡性組成物の使用
PE20081788A1 (es) Combinaciones farmaceuticas
Feldstein et al. Antifungal therapy for onychomycosis in children
Colla et al. Serotonergic and noradrenergic systems are implicated in the antidepressant-like effect of ursolic acid in mice
Jain et al. Evaluation of efficacy of oral pregabalin in reducing postoperative pain in patients undergoing total knee arthroplasty
AR039744A1 (es) Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
BRPI0707235B1 (pt) formulação de fentanil sublingual sem propelente, e, dispositivo de dose unitária para administração sublingual de uma formulação de fentanil sublingual
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR060836A1 (es) Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido
AR076153A1 (es) Forma de dosificacion intra-oral de multiples porciones con propiedades organolepticas. formulaciones
AR079726A1 (es) Terapia combinada para enfermedad pulmonar obstructiva cronica (epoc) . composicion farmaceutica.frasco de aerosol. metodo.conjunto de componentes
BR112014008602A2 (pt) composição farmacêutica, recipiente vedado, inalador de dosagem medida, métodos para o tratamento de um paciente que sofre ou provavelmente sofre de um distúrbio respiratório, e, método para fabricação de uma composição farmacêutica
AR062167A1 (es) Sistema de administracion gastrorretentivo
BR112012030641B8 (pt) Usos e composições para terapia farmacêutica oral
JP2017527608A (ja) 経鼻組成物と該経鼻組成物の使用方法の改善
WO2012040228A3 (en) Aerosol composition for administering drugs
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
BR112015026053A8 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, uso de um componente propelente, e, método para fabricação de uma composição farmacêutica
BRPI0520797B8 (pt) forma de dosagem farmacêutica comprimida em bicamadas
HRP20200142T1 (hr) Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina
BR112021016557A2 (pt) Agente terapêutico inalável
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina

Legal Events

Date Code Title Description
FA Abandonment or withdrawal